#1 Clinical Trials Search in Europe

H2-Receptor Antagonist

This article explores the use of H2-Receptor Antagonists in various clinical trials for cancer treatment. These trials investigate the efficacy and safety of H2-Receptor Antagonists, often in combination with other drugs, for different types of cancer including lung cancer, breast cancer, gastric cancer, urothelial carcinoma, and cervical cancer. The studies aim to evaluate the drug’s potential in improving patient outcomes and quality of life.

Table of Contents

What are H2-Receptor Antagonists?

H2-Receptor Antagonists, also known as H2 blockers, are a class of medications primarily used to treat conditions related to excess stomach acid[1]. These drugs work by blocking histamine receptors in the stomach, which helps reduce the production of stomach acid.

Medical Conditions Treated

H2-Receptor Antagonists are commonly used to treat several gastrointestinal conditions, including:

  • Gastroesophageal reflux disease (GERD): A condition where stomach acid frequently flows back into the esophagus
  • Peptic ulcers: Open sores that develop on the inside lining of the stomach and upper small intestine
  • Dyspepsia: A term for stomach discomfort or indigestion
  • Zollinger-Ellison syndrome: A rare condition that causes tumors in the pancreas or duodenum, leading to increased stomach acid production

Interestingly, recent clinical trials are exploring the potential use of H2-Receptor Antagonists in combination with other drugs for treating various types of cancer[2]. These include non-small cell lung cancer (NSCLC), breast cancer, gastric cancer, and cervical cancer.

How H2-Receptor Antagonists Work

H2-Receptor Antagonists work by blocking the action of histamine on the H2 receptors of the stomach’s parietal cells[3]. Histamine normally stimulates these cells to produce stomach acid. By blocking this action, H2-Receptor Antagonists reduce the amount of acid produced by the stomach, which can help alleviate symptoms and promote healing in conditions related to excess stomach acid.

Administration and Dosage

H2-Receptor Antagonists are typically available in the following forms:

  • Oral tablets or capsules
  • Liquid formulations
  • Intravenous (IV) solutions (in hospital settings)

The dosage and duration of treatment can vary depending on the specific condition being treated and the individual patient’s response. It’s crucial to follow your healthcare provider’s instructions or the directions on the product label carefully[4].

Potential Side Effects

While H2-Receptor Antagonists are generally well-tolerated, they can cause side effects in some people. Common side effects may include:

  • Headache
  • Dizziness
  • Diarrhea or constipation
  • Nausea or vomiting
  • Fatigue

Serious side effects are rare but can include liver problems, changes in heart rhythm, and an increased risk of certain infections. If you experience any unusual or severe side effects, contact your healthcare provider immediately[5].

Ongoing Research

Recent clinical trials are investigating the potential use of H2-Receptor Antagonists in combination with other drugs for cancer treatment. These studies are exploring their efficacy in various types of cancer:

  • Non-small cell lung cancer (NSCLC): A study is evaluating the combination of an H2-Receptor Antagonist with pembrolizumab in patients with resectable stage II to IIIB NSCLC[6].
  • Breast cancer: Research is being conducted on the use of H2-Receptor Antagonists in combination with pembrolizumab for hormone receptor-positive breast cancer[2].
  • Gastric cancer: A clinical trial is comparing an H2-Receptor Antagonist to standard treatment in patients with advanced or metastatic gastric adenocarcinoma[4].
  • Cervical cancer: Researchers are studying the efficacy of an H2-Receptor Antagonist as a second-line treatment for recurrent or metastatic cervical cancer[7].

It’s important to note that these are ongoing studies, and the use of H2-Receptor Antagonists in cancer treatment is not yet approved or established. Patients should not use these medications for cancer treatment outside of clinical trials and without medical supervision.

Conclusion

H2-Receptor Antagonists are valuable medications primarily used to treat conditions related to excess stomach acid. They work by reducing acid production in the stomach, providing relief from symptoms associated with conditions like GERD and peptic ulcers. While generally safe and effective, it’s important to use these medications as directed and be aware of potential side effects. Ongoing research is exploring new potential uses for these drugs, particularly in cancer treatment, but more studies are needed to establish their efficacy in these areas.

Cancer Type Trial Phase Combination Therapy Primary Endpoints
NSCLC Phase III Pembrolizumab PFS, OS
Breast Cancer Phase III Pembrolizumab PFS, OS
Gastric Cancer Phase III None (monotherapy) OS
Urothelial Carcinoma Phase I/II Enfortumab Vedotin, Pembrolizumab Safety, ORR
Cervical Cancer Phase III None (monotherapy) ORR, OS

FAQ

  • What types of cancer are being studied with H2-Receptor Antagonists in these clinical trials? The clinical trials are studying H2-Receptor Antagonists in various types of cancer, including non-small cell lung cancer (NSCLC), breast cancer, gastric cancer, urothelial carcinoma, and cervical cancer.
  • How are H2-Receptor Antagonists being used in these trials? H2-Receptor Antagonists are often being used in combination with other drugs, such as pembrolizumab or enfortumab vedotin. They are being tested as potential treatments for advanced or metastatic cancers, as well as in adjuvant settings after surgery.
  • What are the main objectives of these clinical trials? The main objectives of these trials include evaluating the efficacy and safety of H2-Receptor Antagonists, comparing them to standard treatments, and assessing their impact on patient survival, disease progression, and quality of life.
  • What is the significance of studying H2-Receptor Antagonists in cancer treatment? Studying H2-Receptor Antagonists in cancer treatment is significant because it may lead to new therapeutic options for patients with advanced or hard-to-treat cancers. These trials aim to find more effective treatments with potentially fewer side effects.
  • How do these clinical trials measure the effectiveness of H2-Receptor Antagonists? The effectiveness of H2-Receptor Antagonists is measured through various endpoints, including overall survival (OS), progression-free survival (PFS), objective response rate (ORR), duration of response (DOR), and quality of life assessments using standardized questionnaires.

Ongoing Clinical Trials on H2-Receptor Antagonist

  • Evaluation of Safety and Efficacy of MK-2870 and Paclitaxel in Second-Line Treatment of Advanced/Metastatic Gastroesophageal Adenocarcinoma

    Recruiting

    1 1 1 1
    Investigated drugs:
    France Germany Italy Norway

  • Study on MK-2870, Pembrolizumab, and Chemotherapy for Patients with Advanced Gastroesophageal Cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Norway

  • Study of MK-2870 and Chemotherapy for Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Poland Spain Sweden

  • Study on the Safety and Effectiveness of MK-2870, Enfortumab Vedotin, and Pembrolizumab for Patients with Advanced Bladder Cancer

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Denmark France Italy The Netherlands Spain

Glossary

  • H2-Receptor Antagonist: A type of drug that blocks histamine receptors in the stomach, typically used to reduce stomach acid production. In these trials, it's being studied for potential anti-cancer effects.
  • NSCLC: Non-Small Cell Lung Cancer, a type of lung cancer that is one of the most common forms of the disease.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Adjuvant therapy: Additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back.
  • RECIST 1.1: Response Evaluation Criteria In Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • BICR: Blinded Independent Central Review, an assessment of clinical trial data by experts who are not aware of the treatment assignments.
  • PFS: Progression-Free Survival, the length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • OS: Overall Survival, the length of time from either the date of diagnosis or the start of treatment that patients are still alive.
  • ORR: Objective Response Rate, the proportion of patients whose cancer shrinks or disappears after treatment.
  • DOR: Duration of Response, the length of time that a tumor continues to respond to treatment without the cancer growing or spreading.
  • AE: Adverse Event, any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • QoL: Quality of Life, a measure of an individual's wellbeing and ability to carry out daily activities while dealing with a disease and its treatment effects.
  • EORTC QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, a tool used to assess the quality of life of cancer patients.
  • Urothelial Carcinoma: A type of cancer that typically occurs in the urinary system, including the bladder, ureter, and renal pelvis.
  • Trophoblast cell surface antigen 2 (TROP2): A protein found on the surface of many types of cancer cells, which may be a target for certain cancer treatments.

References

  1. http://clinicaltrials.eu/trial/study-of-mk-2870-and-chemotherapy-for-patients-with-advanced-egfr-mutated-non-small-cell-lung-cancer/
  2. http://clinicaltrials.eu/trial/study-comparing-mk-2870-and-pembrolizumab-with-chemotherapy-for-patients-with-advanced-hormone-receptor-positive-breast-cancer/
  3. http://clinicaltrials.eu/trial/study-of-sacituzumab-tirumotecan-and-pembrolizumab-for-patients-with-triple-negative-breast-cancer-post-surgery/
  4. http://clinicaltrials.eu/trial/study-of-mk-2870-for-patients-with-advanced-or-metastatic-stomach-cancer-comparing-its-effects-to-a-drug-combination/
  5. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-mk-2870-enfortumab-vedotin-and-pembrolizumab-for-patients-with-advanced-bladder-cancer/
  6. http://clinicaltrials.eu/trial/study-of-pembrolizumab-and-mk-2870-for-patients-with-resectable-stage-ii-iiib-nsclc-after-surgery/
  7. http://clinicaltrials.eu/trial/study-of-mk-2870-for-patients-with-recurrent-or-metastatic-cervical-cancer-after-previous-treatments/